J., Sasaki, Y., DiAntonio, A
Semaglutide leans entirely on GLP-1 appetite suppression, slowed gastric emptying, and glucose-dependent insulin release
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist specifically licensed by the MHRA for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity (such as dysglycaemia, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease)
Available at: Aldawsari, M., Almadani, F.A., Almuhammadi, N., Algabsani, S., Alamro, Y
A comprehensive review on compounded semaglutide reported that it is effective at aiding weight loss from the first weeks of treatment onward